Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Strikes Biomarker Discovery Partnership With Cleveland Clinic

NEW YORK — Metabolon said on Thursday that it has signed an agreement to support drug development and related research at the Cleveland Clinic.

Under the terms of the deal, Metabolon will apply its Precision Metabolomics liquid chromatography-mass spectrometry global metabolomics platform — which identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways — to large-scale population health programs underway at the Cleveland Clinic.

Metabolon said that it aims to analyze a range of biological samples to discover metabolomic biomarkers that can help inform these research efforts.

Additional terms of the deal were not disclosed.

"Metabolomics is an essential element of the multi-omics approach that is being employed by Cleveland Clinic to transform healthcare by understanding disease progression and therapeutic response more deeply," Metabolon Scientific Director Greg Michelotti said in a statement.

In August, Morrisville, North Carolina-based Metabolon inked a deal to use its Precision Metabolomics platform to advance drug-development work at Germany's Merck KGaA.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more